The Interaction of Vasopressin and Corticosteroids in Septic Shock: A Pilot Randomized Controlled Trial

Anthony C. Gordon*, Alexina J. Mason, Gavin D. Perkins, Martin Stotz, Marius Terblanche, Deborah Ashby, Stephen J. Brett

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

96 Citations (Scopus)

Abstract

Objectives: Vasopressin and corticosteroids are both commonly used adjunctive therapies in septic shock. Retrospective analyses have suggested that there may be an interaction between these drugs, with higher circulating vasopressin levels and improved outcomes in patients treated with both vasopressin and corticosteroids. We aimed to test for an interaction between vasopressin and corticosteroids in septic shock.

Design: Prospective open-label randomized controlled pilot trial.

Setting: Four adult ICUs in London teaching hospitals.

Patients: Sixty-one adult patients who had septic shock.

Interventions: Initial vasopressin IV infusion titrated up to 0.06 U/min and then IV hydrocortisone (50 mg 6 hourly) or placebo. Plasma vasopressin levels were measured at 6-12 and 24-36 hours after hydrocortisone/placebo administration.

Measurements and Main Results: Thirty-one patients were allocated to vasopressin + hydrocortisone and 30 patients to vasopressin + placebo. The hydrocortisone group required a shorter duration of vasopressin therapy (3.1 d; 95% CI, 1.1-5.1; shorter in hydrocortisone group) and required a lower total dose of vasopressin (ratio, 0.47; 95% CI, 0.32-0.71) compared with the placebo group. Plasma vasopressin levels were not higher in the hydrocortisone group compared with the placebo group (64 pmol/L difference at 6- to 12-hour time point; 95% CI, -32 to 160 pmol/L). Early vasopressin use was well tolerated with only one serious adverse event possibly related to study drug administration reported. There were no differences in mortality rates (23% 28-day mortality in both groups) or organ failure assessments between the two treatment groups.

Conclusions: Hydrocortisone spared vasopressin requirements, reduced duration, and reduced dose, when used together in the treatment of septic shock, but it did not alter plasma vasopressin levels. Further trials are needed to assess the clinical effectiveness of vasopressin as the initial vasopressor therapy with or without corticosteroids.

Original languageEnglish
Pages (from-to)1325-1333
Number of pages9
JournalCritical Care Medicine
Volume42
Issue number6
DOIs
Publication statusPublished - Jun 2014

Keywords

  • adrenal cortex hormones
  • drug interactions
  • intensive care
  • multiple organ failure
  • sepsis
  • vasopressins
  • ADVANCED VASODILATORY SHOCK
  • ATRIAL-NATRIURETIC-PEPTIDE
  • SURVIVING SEPSIS CAMPAIGN
  • LOW-DOSE VASOPRESSIN
  • ACUTE KIDNEY INJURY
  • ARGININE-VASOPRESSIN
  • ORGAN FAILURE
  • INTERNATIONAL GUIDELINES
  • CONSENSUS CONFERENCE
  • NOREPINEPHRINE

Fingerprint

Dive into the research topics of 'The Interaction of Vasopressin and Corticosteroids in Septic Shock: A Pilot Randomized Controlled Trial'. Together they form a unique fingerprint.

Cite this